The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase III trial comparing atezolizumab with enzalutamide vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC).
 
Thomas Powles
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Merck; Novartis
Research Funding - AstraZeneca/MedImmune; Roche/Genentech
 
Karim Fizazi
Honoraria - Amgen; Astellas Pharma; Janssen; Merck; Sanofi; Takeda
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Clovis Oncology; Curevac; ESSA; Janssen Oncology; Orion; Roche/Genentech; Sanofi
Travel, Accommodations, Expenses - Amgen
 
Silke Gillessen
Consulting or Advisory Role - Active Biotech (Inst); Advanced Accelerator Applications (Inst); Astellas Pharma (Inst); Bayer; Bristol-Myers Squibb (Inst); Curevac (Inst); Dendreon; Ferring (Inst); Janssen-Cilag; MaxiVax ; Millennium; Novartis (Inst); Orion; pfizer; Roche (Inst); Sanofi
Patents, Royalties, Other Intellectual Property - Method for biomarker (WO 3752009138392 A1)
Travel, Accommodations, Expenses - Diverse Companies
Other Relationship - ESSA; Nektar; ProteoMediX
 
Charles G. Drake
Stock and Other Ownership Interests - Compugen; ImmunExcite; NexImmune; Potenza Therapeutics; Tizona Therapeutics, Inc.
Consulting or Advisory Role - Agenus; Astellas Medivation; AstraZeneca/MedImmune; Bristol-Myers Squibb (Inst); Compugen; Dendreon; ImmuneXcite; Janssen Oncology; Lilly; Merck; NexImmune; Pfizer; Pierre Fabre; Potenza Therapeutics; Roche/Genentech; Tizona Therapeutics, Inc.
Research Funding - Aduro Biotech (Inst); Bristol-Myers Squibb (Inst); Compugen (Inst); Janssen Oncology (Inst)
Patents, Royalties, Other Intellectual Property - Patents licensed to BMS (Inst); Patents licensed to Potenza Therapeutics (Inst)
 
Dana E. Rathkopf
Consulting or Advisory Role - Janssen Oncology
Research Funding - AstraZeneca (Inst); Celgene (Inst); Ferring (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Medivation (Inst); Millennium (Inst); Novartis (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TRACON Pharma (Inst)
 
Sujata Narayanan
No Relationships to Disclose
 
Marjorie C. Green
Employment - Genentech/Roche
Stock and Other Ownership Interests - Genentech/Roche
 
Almut Mecke
No Relationships to Disclose
 
Christina Schiff
Employment - Genentech
Stock and Other Ownership Interests - Genentech
 
Christopher Sweeney
Stock and Other Ownership Interests - Leuchemix
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Genentech/Roche; Janssen Biotech; Pfizer; Sanofi
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Exelixis (Inst); Janssen Biotech (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Leuchemix, Parthenolide, Dimethylaminoparthenolide. Exelixis: Abiraterone plus cabozantinib combination